Black Diamond Therapeutics (BDTX)

• Market cap: $95.1M
• 1 day: -5.68%
• 5 days: -8.29%
• 1 month: -5.14%
• 3 months: -35.41%
• 6 months: -36.88%
• Year to date: -33.33%
• 1 year: -40.29%
• 5 years: -82.25%
• 10 years: -95.8%
• Sector: Healthcare
• Industry: Biotechnology

About: Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Employees: 21